TMCnet News
Global Companion Diagnostics IndustryNEW YORK, Nov. 15, 2018 /PRNewswire/ -- This report analyzes the worldwide markets for Companion Diagnostics in US$ Million. 5.1. Focus on Select Global Players Abbott Molecular (USA) Agilent Technologies, Inc. (USA) bioMérieux SA (France) Danaher Corporation (USA) Cepheid (USA) Leica Biosystems Nussloch GmbH (Germany) F. Hoffmann-La Roche Ltd. (Switzerland) Foundation Medicine, Inc. (USA) Laboratory Corporation of America® Holdings (USA) Merck & Co. Inc. (USA) Myriad Genetics, Inc. (USA) NeoGenomics, Inc. (USA) QIAGEN N.V. (Netherlands) Quest Diagnostics, Inc. (USA) Thermo Fisher Scientific, Inc. (USA) 5.2 Product Approvals/Launches Foundation Medicine Unveils FoundationOne CDx™ Agilent Bags FDA Approval for Dako PD-L1 IHC 22C3 pharmDx Assay for Expanded Use in Urothelial Carcinoma Roche Receives US FDA Approval for PMA Supplement for cobas® EGFR Mutation Test v2 Myriad Bags Manufacturing & Marketing Approval for BRACAnalysis® Diagnostic System in Japan Roche Wins US FDA Approval for cobas® EGFR Mutation Test v2 as a CDx with IRESSA® Myriad Genetics Bags US FDA Approval for BRACAnalysis CDx® MolecularMD Bags US FDA Authorization for CDx to Novartis CML Drug Thermo Fisher Scientific Receives US FDA Approval for Oncomine™ Dx Target Test for Three NSCLC Treatments 5.3 Recent Industry Activity Roche to Fully Acquire Foundation Medicine Thermo Fisher Scientific Joins Hands with Takeda Pharmaceutical and Daiichi Sankyo Spectrum Pharmaceuticals Inks NGS Companion Diagnostic Partnership with Thermo Fisher Scientific Qiagen and Freenome to Develop NGS-based Companion Diagnostics Bristol-Myers Squibb Joins Hands with Illumina QIAGEN to Acquire STAT-Dx PPD forms Strategic Alliance with NeoGenomics LabCorp Collaborates with Unilabs Merck KGaA and ArcherDX to Develop NGS-based CDx Assay QIAGEN Teams Up with SRL Shuwen Biotech Partners with Bliss Biopharmaceutical Foundation Medicine and Merck to Develop CDx Tests Pierre Fabre Extends CDx Collaboration with Roche Agena Bioscience Inks CDx Collaboration Deal with Simcere Diagnostics in China Foundation Medicine Inks CDx Partnership Deal with Pfizer NeoGenomics to Join Thermo Fisher's CDx Center of Excellence Program LabCorp® Inaugurates New Covance CDx Facility in North Carolina Myriad Genetics Signs CDx Development Collaboration Deal with BeiGene Myriad Genetics to Provide BRACAnalysis CDx® to Clovis Oncology Loxo Oncology Inks Collaboration Agreement with Ventana Medical Systems Thermo Fisher Scientific Inks New Oncology CDx Development Agreement with Blueprint Medicines Thermo Fisher Scientific Partners with Agios Pharmaceuticals Cancer Genetics and LabCorp Join Thermo Fisher's CDx Center of Excellence Program Bristol-Myers Squibb Joins Hands with GRAIL Bristol-Myers Squibb Teams Up with QIAGEN 6. GLOBAL MARKET PERSPECTIVE Table 20: World Recent Past, Current & Future Analysis for Companion Diagnostics Market by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 21: World 5-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Dollar Revenues for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2018 & 2022 (includes corresponding Graph/Chart) By Application Table 22: World Recent Past, Current & Future Analysis for Companion Diagnostics Market by Application Segment - Oncology, Neurology, and Others Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2 through 2022 (includes corresponding Graph/Chart) Table 23: World 5-Year Perspective for Companion Diagnostics by Application Segment - Percentage Breakdown of Dollar Revenues for Oncology, Neurology, and Others Markets for Years 2018 & 2022 (includes corresponding Graph/Chart) 7. REGIONAL MARKET PERSPECTIVE 7.1 The United States A.Market Analysis The United States: Prime Market for Companion Diagnostics Table 24: US Accounts for over 2/5th of World CDx Market: Percentage Breakdown of CDx Revenues for US and Rest of World (2018E and 2022P) (includes corresponding Graph/Chart) Companion Diagnostics Augur Well for Pharmaceutical Companies with Diagnostic Capabilities Growing Cancer Incidence - An Opportunity Indicator for Companion Diagnostics Table 25: Cancer Incidence in the US by Gender (2018E): Estimated New Cases for Men and Women (includes corresponding Graph/Chart) Table 26: Cancer Incidence in the US by Gender (2018E): Estimated Deaths for Men and Women (includes corresponding Graph/Chart) Pioneering Efforts in Oncology CDx Testing Robust Personalized Medicine Market Offers Potential Table 27: US Personalized Medicine Market: Breakdown of Revenues (in US$ Billion) for 2014, 2018E and 2022P (includes corresponding Graph/Chart) Biomarkers: A Novel Paradigm in Companion Diagnostics List of US-FDA Approved Biomarkers for Cancer Ageing Demographics: A Key Market Driver Table 28: North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart) Competitive Scenario Regulatory Overview FDA Requirements in Drug Development Fuel Demand Table 29: Rise in CDx Numbers Over the Years: Number of FDA-Approved Drugs Requiring CDx for Year 1998, 2005, 2008 & 2016 (includes corresponding Graph/Chart) List of FDA-Approved Companion Diagnostics: As of H1 2018 Table 30: Leading FDA-Approved CDx Drugs in the US (2016): Percentage Breakdown of Revenues for Erbitux/Vectibix, Gleevec, Herceptin, Lynparza, Mekinist+Tafinlar, Perjeta, Tarceva, and Others (includes corresponding Graph/Chart) B.Market Analytics Table 31: The US Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 32: The US Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 7.2 Canada A.Market Analysis Higher R&D Spending to Underpin CDx Revenues Cancer Incidence in Canada: Opportunity Indicator for Companion Diagnostics Table 33: New Cancer Cases in Canada by Gender (2017): Breakdown of Cancer Incidence for Male and Female Population (in Thousands) (includes corresponding Graph/Chart) Table 34: Cancer Related Deaths in Canada (2017): Percentage Breakdown of Number of Deaths by Gender and Affected Site (includes corresponding Graph/Chart) Regulatory Scenario B.Market Analytics Table 35: Canadian Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) 7.3 Japan A.Market Analysis Graying Population Spurs Growth Table 36: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart) Table 37: Japanese Population by Age Group (2017): Percentage Breakdown for 0-14 Years, 15-24 Years, 25- Years, 55-64 Years, 65 Years and Above (includes corresponding Graph/Chart) B.Market Analytics Table 38: Japanese Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 39: Japanese Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 7.4 Europe A.Market Analysis A Mature yet Growing Market CDx Gain from Healthy Momentum in Research Programs Growing Role of Personalized Medicine Bodes Well for CDx Table 40: Europe Personalized Medicine Market: Breakdown of Revenues (in US$ Billion) for 2014, 2018E and 2022P (includes corresponding Graph/Chart) Cancer Incidence in Europe: An Opportunity Indicator Table 41: Number of New Cancer Cases in Europe: 2012-2 (includes corresponding Graph/Chart) Ageing Population Drives Demand Table 42: EU-28 Country-wise Statistics of 65+ Population as % of Total Population: 2016 (includes corresponding Graph/Chart) Regulatory Scenario in Europe B.Market Analytics Table 43: European Recent Past, Current & Future Analysis for Companion Diagnostics Market by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 44: European Historic Review for Companion Diagnostics Market by Geographic Region - France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2 through 2014 (includes corresponding Graph/Chart) Table 45: European 5-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Dollar Revenues for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2018 & 2022 (includes corresponding Graph/Chart) 7.4.1 France Market Analysis Table 46: French Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 47: French Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 7.4.2 Germany Market Analysis Table 48: German Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 49: German Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 7.4.3 Italy Market Analysis Table 50: Italian Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 51: Italian Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 7.4.4 The United Kingdom Market Analysis Table 52: The UK Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 53: The UK Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 7.4.5 Spain Market Analysis Table 54: Spanish Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 55: Spanish Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 7.4.6 Rest of Europe Market Analysis Table 56: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2 (includes corresponding Graph/Chart) Table 57: Rest of Europe Historic Review for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) 7.5 Asia-Pacific A.Market Analysis A Rapidly Growing Market Uptrend in IVD Sales Augurs Well for Market Growth B.Market Analytics Table 58: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics Market by Geographic Region - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) Table 59: Asia-Pacific 5-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Dollar Revenues for China and Rest of Asia-Pacific Markets for Years 2018 & 2022 (includes corresponding Graph/Chart) 7.5.1 China A.Market Analysis Breast Cancer CDx: Dominant Category Laboratory Equipment & Supplies Sector in China: An Overview B.Market Analytics Table 60: Chinese Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) 7.5.2 Rest of Asia-Pacific Market Analysis Table 61: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) 7.6 Latin America Market Analysis Table 62: Latin American Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed with Annual Revenue Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) 7.7 Rest of World Market Analysis Table 63: Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics Market Analyzed by Annual Revenue Figures in US$ Million for Years 2015 through 2 (includes corresponding Graph/Chart) 8. COMPANY PROFILES Total Companies Profiled: 80 (including Divisions/Subsidiaries - 89) The United States (53) Canada (2) Europe (28) - France (5) - Germany (4) - The United Kingdom (9) - Spain (1) - Rest of Europe (9) Asia-Pacific (Excluding Japan) (5) Middle East (1) Read the full report: https://www.reportlinker.com/p03915705 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001 View original content:http://www.prnewswire.com/news-releases/global-companion-diagnostics-industry-300751526.html SOURCE Reportlinker |